Fulcrum Therapeutics, Inc.
FULC
$3.52
$0.082.33%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0.00 | 0.00 | 80.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 0.00 | 0.00 | 80.00M |
| Cost of Revenue | 56.78M | 56.10M | 52.40M | 52.74M | 57.02M |
| Gross Profit | -56.78M | -56.10M | -52.40M | -52.74M | 22.98M |
| SG&A Expenses | 29.77M | 28.67M | 29.11M | 29.97M | 33.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 86.55M | 84.77M | 81.51M | 82.71M | 90.40M |
| Operating Income | -86.55M | -84.77M | -81.51M | -82.71M | -10.40M |
| Income Before Tax | -76.12M | -74.88M | -71.11M | -73.22M | -510.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -76.12 | -74.88 | -71.11 | -73.22 | -0.51 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -76.12M | -74.88M | -71.11M | -73.22M | -510.00K |
| EBIT | -86.55M | -84.77M | -81.51M | -82.71M | -10.40M |
| EBITDA | -85.18M | -83.38M | -80.09M | -81.28M | -8.94M |
| EPS Basic | -1.15 | -1.18 | -1.18 | -1.21 | -0.05 |
| Normalized Basic EPS | -0.72 | -0.74 | -0.74 | -0.74 | -0.01 |
| EPS Diluted | -1.15 | -1.19 | -1.19 | -1.22 | -0.07 |
| Normalized Diluted EPS | -0.72 | -0.74 | -0.74 | -0.74 | -0.02 |
| Average Basic Shares Outstanding | 267.14M | 253.40M | 241.57M | 241.39M | 241.05M |
| Average Diluted Shares Outstanding | 267.14M | 253.40M | 241.57M | 241.39M | 242.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |